Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
2.

Inflammation, Immunity, and Oxidative Stress in Hypertension-Partners in Crime?

Barrows IR, Ramezani A, Raj DS.

Adv Chronic Kidney Dis. 2019 Mar;26(2):122-130. doi: 10.1053/j.ackd.2019.03.001. Review.

PMID:
31023446
3.

Blood Microbiome Profile in CKD : A Pilot Study.

Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS, Fasano A.

Clin J Am Soc Nephrol. 2019 May 7;14(5):692-701. doi: 10.2215/CJN.12161018. Epub 2019 Apr 8.

PMID:
30962186
4.

Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease.

Chen J, Bundy JD, Hamm LL, Hsu CY, Lash J, Miller ER 3rd, Thomas G, Cohen DL, Weir MR, Raj DS, Chen HY, Xie D, Rao P, Wright JT Jr, Rahman M, He J.

Hypertension. 2019 Apr;73(4):785-793. doi: 10.1161/HYPERTENSIONAHA.118.12358.

PMID:
30776971
5.

Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study.

Amdur RL, Feldman HI, Dominic EA, Anderson AH, Beddhu S, Rahman M, Wolf M, Reilly M, Ojo A, Townsend RR, Go AS, He J, Xie D, Thompson S, Budoff M, Kasner S, Kimmel PL, Kusek JW, Raj DS; CRIC Study Investigators.

Am J Kidney Dis. 2019 Mar;73(3):344-353. doi: 10.1053/j.ajkd.2018.09.012. Epub 2018 Dec 10.

6.

Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, Weiner DE, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM; Hemodialysis Novel Therapies Consortium.

Kidney Int. 2019 Apr;95(4):973-982. doi: 10.1016/j.kint.2018.08.034. Epub 2018 Nov 23.

PMID:
30473139
7.

Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD.

Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, Isakova T; CKD Optimal Management with BInders and NicotinamidE (COMBINE) study group.

Kidney Int Rep. 2018 Jul 7;3(6):1467-1472. doi: 10.1016/j.ekir.2018.07.006. eCollection 2018 Nov. No abstract available.

8.

Gut Colonization with Methanogenic Archaea Lowers Plasma Trimethylamine N-oxide Concentrations in Apolipoprotein e-/- Mice.

Ramezani A, Nolin TD, Barrows IR, Serrano MG, Buck GA, Regunathan-Shenk R, West RE 3rd, Latham PS, Amdur R, Raj DS.

Sci Rep. 2018 Oct 3;8(1):14752. doi: 10.1038/s41598-018-33018-5.

9.

Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants.

Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M.

PLoS One. 2018 Sep 26;13(9):e0203305. doi: 10.1371/journal.pone.0203305. eCollection 2018.

10.

Gut Microbiota and Cardiovascular Uremic Toxicities.

Velasquez MT, Centron P, Barrows I, Dwivedi R, Raj DS.

Toxins (Basel). 2018 Jul 11;10(7). pii: E287. doi: 10.3390/toxins10070287. Review.

11.

A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.

Yang S, Ambrosius WT, Fine LJ, Bress AP, Cushman WC, Raj DS, Rehman S, Tamariz L.

Clin Trials. 2018 Jun;15(3):305-312. doi: 10.1177/1740774518769865. Epub 2018 Apr 19.

PMID:
29671345
12.

Principles of quantitative water and electrolyte replacement of losses from osmotic diuresis.

Roumelioti ME, Ing TS, Rondon-Berrios H, Glew RH, Khitan ZJ, Sun Y, Malhotra D, Raj DS, Agaba EI, Murata GH, Shapiro JI, Tzamaloukas AH.

Int Urol Nephrol. 2018 Jul;50(7):1263-1270. doi: 10.1007/s11255-018-1822-0. Epub 2018 Mar 6. Review.

PMID:
29511980
13.

Fluid balance concepts in medicine: Principles and practice.

Roumelioti ME, Glew RH, Khitan ZJ, Rondon-Berrios H, Argyropoulos CP, Malhotra D, Raj DS, Agaba EI, Rohrscheib M, Murata GH, Shapiro JI, Tzamaloukas AH.

World J Nephrol. 2018 Jan 6;7(1):1-28. doi: 10.5527/wjn.v7.i1.1. Review.

14.

Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate.

Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, Rohrscheib M, Shapiro JI, Tzamaloukas AH.

World J Methodol. 2017 Sep 26;7(3):73-92. doi: 10.5662/wjm.v7.i3.73. eCollection 2017 Sep 26. Review.

15.

Racial/Ethnic Differences in Left Ventricular Structure and Function in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort.

Ahmad FS, Cai X, Kunkel K, Ricardo AC, Lash JP, Raj DS, He J, Anderson AH, Budoff MJ, Wright Nunes JA, Roy J, Wright JT Jr, Go AS, St John Sutton MG, Kusek JW, Isakova T, Wolf M, Keane MG; CRIC Study Investigators.

Am J Hypertens. 2017 Aug 1;30(8):822-829. doi: 10.1093/ajh/hpx058.

16.

Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.

Upadhya B, Rocco M, Lewis CE, Oparil S, Lovato LC, Cushman WC, Bates JT, Bello NA, Aurigemma G, Fine LJ, Johnson KC, Rodriguez CJ, Raj DS, Rastogi A, Tamariz L, Wiggers A, Kitzman DW; SPRINT Research Group.

Circ Heart Fail. 2017 Apr;10(4). pii: e003613. doi: 10.1161/CIRCHEARTFAILURE.116.003613.

17.

Gut Microbiome in Chronic Kidney Disease.

Armani RG, Ramezani A, Yasir A, Sharama S, Canziani MEF, Raj DS.

Curr Hypertens Rep. 2017 Apr;19(4):29. doi: 10.1007/s11906-017-0727-0. Review.

PMID:
28343357
18.

Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?

Velasquez MT, Beddhu S, Nobakht E, Rahman M, Raj DS.

Kidney Int Rep. 2016 Jul;1(2):94-104. doi: 10.1016/j.ekir.2016.05.001. Epub 2016 Jun 4.

19.

Hypertonicity: Clinical entities, manifestations and treatment.

Rondon-Berrios H, Argyropoulos C, Ing TS, Raj DS, Malhotra D, Agaba EI, Rohrscheib M, Khitan ZJ, Murata GH, Shapiro JI, Tzamaloukas AH.

World J Nephrol. 2017 Jan 6;6(1):1-13. doi: 10.5527/wjn.v6.i1.1. Review.

20.

Extracellular microRNA signature in chronic kidney disease.

Muralidharan J, Ramezani A, Hubal M, Knoblach S, Shrivastav S, Karandish S, Scott R, Maxwell N, Ozturk S, Beddhu S, Kopp JB, Raj DS.

Am J Physiol Renal Physiol. 2017 Jun 1;312(6):F982-F991. doi: 10.1152/ajprenal.00569.2016. Epub 2017 Jan 11.

21.

Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.

Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M; CRIC Study Investigators.

Kidney Int. 2017 Mar;91(3):711-719. doi: 10.1016/j.kint.2016.10.021. Epub 2016 Dec 22.

22.

Trimethylamine N-Oxide: The Good, the Bad and the Unknown.

Velasquez MT, Ramezani A, Manal A, Raj DS.

Toxins (Basel). 2016 Nov 8;8(11). pii: E326. Review.

23.

CKD Progression and Mortality among Hispanics and Non-Hispanics.

Fischer MJ, Hsu JY, Lora CM, Ricardo AC, Anderson AH, Bazzano L, Cuevas MM, Hsu CY, Kusek JW, Renteria A, Ojo AO, Raj DS, Rosas SE, Pan Q, Yaffe K, Go AS, Lash JP; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2016 Nov;27(11):3488-3497. Epub 2016 May 5.

24.

Hypertonicity: Pathophysiologic Concept and Experimental Studies.

Argyropoulos C, Rondon-Berrios H, Raj DS, Malhotra D, Agaba EI, Rohrscheib M, Khitan Z, Murata GH, Shapiro JI, Tzamaloukas AH.

Cureus. 2016 May 2;8(5):e596. doi: 10.7759/cureus.596. Review.

25.

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.

Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT Jr, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J.

Kidney Int. 2016 Aug;90(2):440-449. doi: 10.1016/j.kint.2016.04.027. Epub 2016 Jun 22.

26.

Inflammation and Progression of CKD: The CRIC Study.

Amdur RL, Feldman HI, Gupta J, Yang W, Kanetsky P, Shlipak M, Rahman M, Lash JP, Townsend RR, Ojo A, Roy-Chaudhury A, Go AS, Joffe M, He J, Balakrishnan VS, Kimmel PL, Kusek JW, Raj DS; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1546-56. doi: 10.2215/CJN.13121215. Epub 2016 Jun 23.

27.

Janus Face of Coronary Artery Disease and Chronic Kidney Disease.

Barrows IR, Raj DS.

J Am Heart Assoc. 2016 Apr 23;5(4). pii: e003596. doi: 10.1161/JAHA.116.003596. No abstract available.

28.

Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study.

Amdur RL, Mukherjee M, Go A, Barrows IR, Ramezani A, Shoji J, Reilly MP, Gnanaraj J, Deo R, Roas S, Keane M, Master S, Teal V, Soliman EZ, Yang P, Feldman H, Kusek JW, Tracy CM, Raj DS; CRIC Study Investigators.

PLoS One. 2016 Feb 3;11(2):e0148189. doi: 10.1371/journal.pone.0148189. eCollection 2016.

29.

Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.

Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS.

Am J Kidney Dis. 2016 Mar;67(3):483-98. doi: 10.1053/j.ajkd.2015.09.027. Epub 2015 Nov 15. Review.

30.

Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD.

Navaneethan SD, Roy J, Tao K, Brecklin CS, Chen J, Deo R, Flack JM, Ojo AO, Plappert TJ, Raj DS, Saydain G, Sondheimer JH, Sood R, Steigerwalt SP, Townsend RR, Dweik RA, Rahman M; Chronic Renal Insufficiency Cohort Investigators.

J Am Soc Nephrol. 2016 Mar;27(3):877-86. doi: 10.1681/ASN.2014111111. Epub 2015 Sep 18.

31.

Gut microbiome in chronic kidney disease.

Wing MR, Patel SS, Ramezani A, Raj DS.

Exp Physiol. 2016 Apr;101(4):471-7. doi: 10.1113/EP085283. Epub 2015 Oct 2. Review.

32.

Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD.

Poesen R, Ramezani A, Claes K, Augustijns P, Kuypers D, Barrows IR, Muralidharan J, Evenepoel P, Meijers B, Raj DS.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1525-33. doi: 10.2215/CJN.03100315. Epub 2015 Jul 7.

33.

Stimulation of Liver X Receptor Has Potent Anti-HIV Effects in a Humanized Mouse Model of HIV Infection.

Ramezani A, Dubrovsky L, Pushkarsky T, Sviridov D, Karandish S, Raj DS, Fitzgerald ML, Bukrinsky M.

J Pharmacol Exp Ther. 2015 Sep;354(3):376-83. doi: 10.1124/jpet.115.224485. Epub 2015 Jun 30.

34.

Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?

Velasquez MT, Ramezani A, Raj DS.

Kidney Int. 2015 Jun;87(6):1092-4. doi: 10.1038/ki.2015.78.

35.

Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study.

Gupta J, Dominic EA, Fink JC, Ojo AO, Barrows IR, Reilly MP, Townsend RR, Joffe MM, Rosas SE, Wolman M, Patel SS, Keane MG, Feldman HI, Kusek JW, Raj DS; CRIC Study Investigators.

PLoS One. 2015 Apr 24;10(4):e0124772. doi: 10.1371/journal.pone.0124772. eCollection 2015.

36.

Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Shah R, Matthews GJ, Shah RY, McLaughlin C, Chen J, Wolman M, Master SR, Chai B, Xie D, Rader DJ, Raj DS, Mehta NN, Budoff M, Fischer MJ, Go AS, Townsend RR, He J, Kusek JW, Feldman HI, Foulkes AS, Reilly MP; CRIC Study Investigators.

Am J Kidney Dis. 2015 Aug;66(2):266-73. doi: 10.1053/j.ajkd.2015.01.021. Epub 2015 Mar 17.

37.

Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.

Ramezani A, Devaney JM, Cohen S, Wing MR, Scott R, Knoblach S, Singhal R, Howard L, Kopp JB, Raj DS.

Eur J Clin Invest. 2015 Apr;45(4):394-404. doi: 10.1111/eci.12420.

38.

Gut Feeling in AKI: The Long Arm of Short-Chain Fatty Acids.

Barrows IR, Ramezani A, Raj DS.

J Am Soc Nephrol. 2015 Aug;26(8):1755-7. doi: 10.1681/ASN.2014111157. Epub 2015 Jan 14. No abstract available.

39.

Management of severe hyponatremia: infusion of hypertonic saline and desmopressin or infusion of vasopressin inhibitors?

Tzamaloukas AH, Shapiro JI, Raj DS, Murata GH, Glew RH, Malhotra D.

Am J Med Sci. 2014 Nov;348(5):432-9. doi: 10.1097/MAJ.0000000000000331. Review.

40.

Electroacupuncture therapy for muscle atrophy in CKD: is there a needle in the haystack?

Ramezani A, Barrows IR, Raj DS.

J Am Soc Nephrol. 2015 Mar;26(3):510-2. doi: 10.1681/ASN.2014080781. Epub 2014 Sep 16. No abstract available.

41.

Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.

Rambod M, Heine GH, Seiler S, Dominic EA, Rogacev KS, Dwivedi R, Ramezani A, Wing MR, Amdur RL, Fliser D, Raj DS.

Atherosclerosis. 2014 Oct;236(2):360-5. doi: 10.1016/j.atherosclerosis.2014.07.026. Epub 2014 Aug 12.

42.

Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial.

Langefeld CD, Divers J, Pajewski NM, Hawfield AT, Reboussin DM, Bild DE, Kaysen GA, Kimmel PL, Raj DS, Ricardo AC, Wright JT Jr, Sedor JR, Rocco MV, Freedman BI; Systolic Blood Pressure Intervention Trial (SPRINT).

Kidney Int. 2015 Jan;87(1):169-75. doi: 10.1038/ki.2014.254. Epub 2014 Jul 16.

43.

Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.

Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, He J, Raj DS, Schelling J, Strauss L, Teal V, Rader DJ; CRIC Study Investigators.

Clin J Am Soc Nephrol. 2014 Jul;9(7):1190-8. doi: 10.2215/CJN.09320913. Epub 2014 May 15.

44.

DNA methylation profile associated with rapid decline in kidney function: findings from the CRIC study.

Wing MR, Devaney JM, Joffe MM, Xie D, Feldman HI, Dominic EA, Guzman NJ, Ramezani A, Susztak K, Herman JG, Cope L, Harmon B, Kwabi-Addo B, Gordish-Dressman H, Go AS, He J, Lash JP, Kusek JW, Raj DS; Chronic Renal Insufficiency Cohort (CRIC) Study.

Nephrol Dial Transplant. 2014 Apr;29(4):864-72. doi: 10.1093/ndt/gft537. Epub 2014 Feb 9.

45.

Race modifies the association between adiposity and inflammation in patients with chronic kidney disease: findings from the chronic renal insufficiency cohort study.

Wing MR, Yang W, Teal V, Navaneethan S, Tao K, Ojo A, Guzman NN, Reilly M, Wolman M, Rosas SE, Cuevas M, Fischer M, Lustigova E, Master SR, Xie D, Appleby D, Joffe M, Kusek J, Feldman HI, Raj DS; Chronic Renal Insufficiency Cohort (CRIC) Study.

Obesity (Silver Spring). 2014 May;22(5):1359-66. doi: 10.1002/oby.20692. Epub 2014 Feb 11.

46.

A systems analysis of age-related changes in some cardiac aging traits.

Govindaraju DR, Pencina KM, Raj DS, Massaro JM, Carnes BA, D'Agostino RB.

Biogerontology. 2014 Apr;15(2):139-52. doi: 10.1007/s10522-013-9486-8. Epub 2013 Dec 14.

PMID:
24337960
47.

The gut microbiome, kidney disease, and targeted interventions.

Ramezani A, Raj DS.

J Am Soc Nephrol. 2014 Apr;25(4):657-70. doi: 10.1681/ASN.2013080905. Epub 2013 Nov 14. Review.

48.

APOL1 risk variants, race, and progression of chronic kidney disease.

Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators.

N Engl J Med. 2013 Dec 5;369(23):2183-96. doi: 10.1056/NEJMoa1310345. Epub 2013 Nov 9.

49.

Fibroblast growth factor-23 and cardiovascular events in CKD.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2014 Feb;25(2):349-60. doi: 10.1681/ASN.2013050465. Epub 2013 Oct 24.

50.

Epigenetics of progression of chronic kidney disease: fact or fantasy?

Wing MR, Ramezani A, Gill HS, Devaney JM, Raj DS.

Semin Nephrol. 2013 Jul;33(4):363-74. doi: 10.1016/j.semnephrol.2013.05.008. Review.

Supplemental Content

Support Center